Taysha Gene Therapies, Inc. (TSHA) stock
TSHANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$3.99−0.01 (-0.25%)
Close on Nov 18, 2026Market cap $1.30BP/E –Yield –
Taysha Gene Therapies revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Taysha Gene Therapies's revenue for the twelve months ending Jun 30, 2026 was $5.49M, down 32.3% year over year. For fiscal 2025 it was $9.77M, up 17.3% from the year before.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $9.77M | +17.3% |
| FY2024 | Dec 31, 2024 | $8.33M | -46.1% |
| FY2023 | Dec 31, 2023 | $15.45M | +517.5% |
| FY2022 | Dec 31, 2022 | $2.50M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $0 | -100.0% |
| Q1 FY2026 | Mar 31, 2026 | $0 | -100.0% |
| Q4 FY2025 | Dec 31, 2025 | $5.49M | +171.3% |
| Q3 FY2025 | Sep 30, 2025 | $0 | -100.0% |
| Q2 FY2025 | Jun 30, 2025 | $1.99M | +78.6% |
| Q1 FY2025 | Mar 31, 2025 | $2.30M | -32.5% |
| Q4 FY2024 | Dec 31, 2024 | $2.02M | -43.9% |
| Q3 FY2024 | Sep 30, 2024 | $1.79M | -62.3% |
| Q2 FY2024 | Jun 30, 2024 | $1.11M | -53.6% |
| Q1 FY2024 | Mar 31, 2024 | $3.41M | -27.5% |
| Q4 FY2023 | Dec 31, 2023 | $3.60M | – |
| Q3 FY2023 | Sep 30, 2023 | $4.75M | – |
| Q2 FY2023 | Jun 30, 2023 | $2.40M | – |
| Q1 FY2023 | Mar 31, 2023 | $4.71M | – |
See a number that looks wrong?